A new pre grant opposition decision is uploaded in IPO site. Application NO: 593/CHENP/2005 is assigned to Novartis and Titled “Dispersible tablets comprising deferacirox”. This application is opposed by Cipla under 25(1).
This application is refused under lack of inventive step 25(1) (e) and Not an invention 25(1) (f). Interestingly, Controller provides requirement of composition claims to satisfy section 3(d) and (e).
As per Controller’s opinion, A composition claim should possess a) all the components of the invention in the principal claim itself, b) all necessary ingredients with proportions of each ingredient, c) some data to support synergy of the composition incorporated in specification.